Lexeo Therapeutics, Inc. Common Stock
Stock Forecast, Prediction & Price Target
Lexeo Therapeutics, Inc. Common Stock Financial Estimates
Lexeo Therapeutics, Inc. Common Stock Revenue Estimates
Lexeo Therapeutics, Inc. Common Stock EBITDA Estimates
Lexeo Therapeutics, Inc. Common Stock Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $1.65M N/A | $654K -60.53% | $0 -100% | Avg: $642.86K Low: $642.86K High: $642.86K avg. 0% | Avg: $1.5M Low: $1.5M High: $1.5M avg. 133.33% | ||
Net Income
% change YoY
| $-50.62M N/A | $-59.27M -17.09% | $-66.39M -12.00% | Avg: $-91.05M Low: $-78.93M High: $-51.29M avg. -37.13% | Avg: $-79.26M Low: $-73.75M High: $-46.74M avg. 12.94% | ||
EBITDA
% change YoY
| $-50.60M N/A | $-58.04M -14.68% | $-66.67M -14.86% | Avg: $-642.86K Low: $-642.86K High: $-642.86K avg. 99.03% | Avg: $-1.5M Low: $-1.5M High: $-1.5M avg. -133.33% | ||
EPS
% change YoY
| -$2.05 N/A | -$2.4 -17.07% | -$2.49 -3.75% | Avg: -$2.63 Low: -$3.2 High: -$2.08 avg. -5.77% | Avg: -$2.44 Low: -$2.99 High: -$1.89 avg. 7.29% | ||
Operating Expenses
% change YoY
| $52.29M N/A | $61.16M 16.95% | $68.51M 12.01% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | ||
FAQ
What is Lexeo Therapeutics, Inc. Common Stock stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -12.09% in 2025-2026.
We have gathered data from 5 analysts. Their low estimate is -78.93M, average is -91.05M and high is -51.29M.
What is Lexeo Therapeutics, Inc. Common Stock stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 66.66% in 2025-2026.
We have gathered data from 6 analysts. Their low revenue estimate is $642.86K, average is $642.86K and high is $642.86K.
What is Lexeo Therapeutics, Inc. Common Stock stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 0.76% in 2025-2026.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$3.2, average is -$2.63 and high is $-2.07.
What is the best performing analyst?
In the last twelve months analysts have been covering Lexeo Therapeutics, Inc. Common Stock stock. The most successful analyst is Brian Skorney.